The Latest Breaking News from Novavax

Pfizer Inc. (NYSE: PFE) and Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 4.3% at $52.42 and 9.6% at $80.05 respectively. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.

France has begun using Novavax, a non-mRNA vaccine, to try and sway the unvaccinated as the number of Covid infections slightly increases raising concerns a sixth wave could be around the corner. But take up is slow.

Novavax Inc (NASDAQ: NVAX) is trading higher Tuesday after the company reported fourth-quarter financial results and issued guidance expecting a surge in revenue.

Novavax (NASDAQ:NVAX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Novavax missed estimated earnings by 521.11%, reporting an EPS of $-11.18 versus an estimate of $-1.8.

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.

Move comes as case numbers and deaths continue to fall in many nations

Someone with a lot of money to spend has taken a bearish stance on Novavax (NASDAQ:NVAX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Latest updates: Germany hopes protein-based vaccine comparable to flu jabs will help sway people sceptical of mRNA vaccines

Leading biotech company Novavax (NVAX) has received temporary approvals for the use of its COVID-19 vaccine from several countries and has filed for emergency use authorization from the U.S. FDA. However, with several high-efficacy vaccines already available in the market, will NVAX be able to successfully commercialize its COVID-19 vaccine…